zinc finger protein 969, pseudogeneGenealiases: []
Q-omics provides the consensus-scored ZNF969P profile across patient tissues and cancer cell-line models. ZNF969P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, ZNF969P is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ZNF969P RNA expression shows 8,774 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ESCA, KIRC, and LSCC as cancer lineages where ZNF969P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF969P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF969P survival associations across molecular data types. ZNF969P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF969P RNA expression–survival associations across cancer types. High ZNF969P expression shows unfavorable associations in THCA, PAAD, HNSC and PRAD, but favorable associations in ESCA and LAML. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify ESCA as the clearest survival context for ZNF969P RNA expression.
This table summarizes ZNF969P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF969P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF969P shows higher tumor expression in KIRC, HNSC, LUSC, BLCA, STAD and THCA. The KIRC box plot shows higher ZNF969P RNA expression in tumor versus normal tissue (log2 FC = +0.041, t-test p < 0.001).
This table shows molecular features associated with ZNF969P in patient tissues and cancer cell lines. In patient samples, ZNF969P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
